Non-euploid embryo transfer for Aneuploidy
This study is evaluating whether embryos that are reported to be abnormal by preimplantation genetic testing result in liveborn infants.
See full descriptionAbout the trial for Aneuploidy
Treatment Groups
This trial involves 2 different treatments. Non-euploid Embryo Transfer is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for female patients between 18 and 65 years old. There are 4 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Non-euploid embryo transfer will improve 1 primary outcome and 3 secondary outcomes in patients with Aneuploidy. Measurement will happen over the course of 7 years 3 months.
Who is running the study
Principal InvestigatorPatient Q & A Section
How many people get aneuploidy a year in the United States?
About 1.3 million people are diagnosed with an aneuploidy in the United States a year. About 80% of patients who have aneuploidy have a normal blood-test result, and these patients have a low risk of inheriting an additional genetic disorder; thus, most individuals probably don’t need genetic screening.
What are common treatments for aneuploidy?
Results from a recent clinical trial adds to the already existing evidence on common treatment therapies for aneuploidy. The list of treatment therapies for aneuploidy is relatively small compared to other conditions and disorders. Further study into the specifics of these treatments is needed.
Can aneuploidy be cured?
Many individuals have chromosome abnormalities that result in an abnormal karyotype and hence an abnormal set of numerical and structural chromosome genes. These may be responsible for some of the clinical features of aneuploidy. Because these abnormalities are often inherited, most individuals with aneuploidy have a normal life span and their phenotype is often mild compared with syndromes caused by mutations in the chromosome sets. Even without clinical signs of aneuploidy, individuals with chromosome abnormalities have a higher prevalence of many genetic and physical disabilities. These disabilities can be a lifelong issue for individuals with chromosome abnormalities, even without clinical signs of aneuploidy and even in the absence of any of the symptoms of an aneuploidy syndrome.
What are the signs of aneuploidy?
The signs and symptoms of aneuploidy vary, depending on the cause. In some cases, there are more complaints from patients, with the presence of more signs, compared with patients without aneuploidy.
What causes aneuploidy?
Abnormal numbers of chromosomes do not necessarily lead to abnormal functioning—it is possible for these abnormalities to occur without any ill effects. This is probably the case with trisomy of chromosome 21, in the case of Down syndrome, since people with this condition usually are of normal intelligence and do not have the characteristic features of severe brain-damaged people with autism. However, people with tetrasomy of chromosome 14, which often causes intellectual disability, are often affected by brain damage and often die in childhood.
What is aneuploidy?
In most cases, aneuploidy is a non-inherited and non-symptomatic disorder. It can be caused by a number of other processes, and in fact seems to be very common. Therefore, aneuploidy is not just a disease entity, but it will need integrated diagnosis, diagnosis, therapy, and even follow up in order to have a better comprehension of its clinical relevance, progression and prognosis. Aneuploidy is the general term and most of its subtypes are well-defined to have more reliable diagnoses and treatments.
Has non-euploid embryo transfer proven to be more effective than a placebo?
Contrary to common beliefs, our study supports the hypothesis that, for ET-cycles, aneuploidy of oocytes and embryo(s) has no positive effect and in contrast is associated with reduced pregnancy and clinical pregnancy rates.
What is non-euploid embryo transfer?
A lower number of embryos retrieved at the time of fertilization is required for those euploid embryos that are transferred as compared with those discarded. This is probably due to both an increased implantation rate and decreased post-fertilization mortality. A policy of embryo transfer only in response to clinical pregnancy offers an efficient use of embryonic resources.
Is non-euploid embryo transfer typically used in combination with any other treatments?
We found no evidence that aneuploid embryos are implanted more frequently in response to adjuvant treatments. For non-complicated IVF-ET, when the embryo scores higher than day 3/4 quality, the resulting pregnancy and implantation rates do not appear to be better than those for those embryos scoring 3/4.
Have there been any new discoveries for treating aneuploidy?
The development of techniques and screening-based approaches to treat aneuploidy has resulted in [an] increased use of therapeutic strategies for treating aneuploidy. It is necessary for patients to become informed regarding these new developments.
What is the latest research for aneuploidy?
The detection and classification of aneuploidy can be a useful tool for identifying candidates for more severe defects that can result in adverse perinatal outcomes, such as trisomy 21 (Down syndrome) or trisomy 18 (Edwards syndrome). The best method to detect aneuploidies is flow cytometry by looking at all chromosomes and at all their banding patterns. However, this technique can be difficult and laborious because it may take up to 2 weeks to complete; it uses a lot of equipment and has a high associated cost; it has a low positive predictive value; and it could be inaccurate if there is a lot of mosaicism or if there are structural and numerical chromosome rearrangements.